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ABSTRACT
EFFICACY OF INTRAVENOUS ONDANSETRON IN RELIEVING
NAUSEA/VOMITING AND PRURITUS POST EPIDURAL
ADMINISTERED OPIOIDS IN THE OBSTETRIC PATIENT
by Benjamin Stephen Butler
December 2016
One prominent side effect in the use of a neuraxial anesthesia is pruritus, with an
incidence in the obstetric patient of 60-100% (Kumar & Singh, 2013). Another side
effect of an epidural placement is nausea and vomiting. Nausea and vomiting occurs
frequently during the progress of labor and is difficult to determine an incidence that is
related to epidural opioid administration (Chestnut et al., 2014). A review of literature
was performed and established evidence that ondansetron is effective in reducing
incidence of pruritus in intrathecal administered opioids for cesarean sections in the
obstetric patient. No literature was found concerning ondansetron reducing either
incidence of nausea/vomiting or pruritus in post epidural administered opioids for
obstetric patient. A retrospective chart review was completed and statistical analysis
concluded that in this sample ondansetron was not effective in reducing nausea/vomiting
or pruritus in the obstetric population (Pruritus p = .195 and Nausea/Vomiting p = .844).
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CHAPTER I - INTRODUCTION
For the obstetric patient population, an epidural is an elective anesthetic procedure
that is used to decrease the pain and discomfort. Epidurals are in a classification of
anesthesia termed neuraxial anesthesia. The administration of a local anesthetic is often
used in combination with an opioid to provide neuraxial analgesia. According to
Chestnut et al. (2014), “neuraxial analgesia is the only form of analgesia that provides
complete analgesia for both stages of labor” (p. 457). The epidural is placed either by the
anesthesia provider and it is the responsibility of the anesthesia provider to care for the
patient until the epidural is discontinued when the obstetric patient delivers her baby.
The anesthesia provider is responsible for ensuring patient safety and managing any
potential side effects. One prominent side effect in the use of a neuraxial anesthesia is
pruritus, with an incidence in the obstetric patient of 60-100% (Kumar & Singh, 2013).
Another side effect of an epidural placement is nausea and vomiting. Nausea and
vomiting occurs frequently during the progress of labor and is difficult to determine an
incidence that is related to epidural opioid administration (Chestnut et al., 2014). These
side effects are not life-threatening but they are undesirable and a discomforting effect of
neuraxial administration of opioids.
Background
In the majority of health care facilities a protocol is established to help alleviate
the effects of nausea/vomiting and pruritus. Currently there is no guideline endorsed by
the American Society of Anesthesiologists (ASA) for these treatments. Treatment is
warranted by patient condition and the preference of the anesthesia provider. The
medications ordered for current treatments are not always effective in relieving the
1

patient of the pruritus. A common first step intervention used in current treatments is the
administration of diphenhydramine. This medication inhibits the release of histamine but
not all neuraxial administered opioids release histamine and the patient may still
complain of pruritus.
Ondansetron is a serotonin (5HT-3) antagonist that is approved by the Food and
Drug Administration (FDA) for treatment of nausea and vomiting. Chestnut et al. (2014)
indicate that, “prophylactic administration of ondansetron 4 to 8 mg has been shown to
have better antiemetic profile in the first 24 hours after intrathecal and epidural opioid
administration when compared with a placebo” (pp. 642-643). Ondansetron also has
been shown to help alleviate the pruritic side effect of neuraxial administered opioids and
does not have the sedative effects commonly seen with diphenhydramine. The exact
mechanism of action for the reduction of pruritus from ondansetron is unknown.
Significance
Starting in January of 2016, the anesthesia department of a southeastern
Mississippi healthcare facility created a four person epidural team consisting of all
CRNAs that assumed the placement and management of epidurals in the obstetric patient.
It was previously performed by the obstetric physicians. Currently in practice, one
CRNA is administering 4mg IV ondansetron within 5 minutes after placement of an
epidural.
Needs Assessment
Osterman and Martin (2011) published in the National Vital Statistics Report that
overall, 61% of women who had a single birth in a vaginal delivery in 2008 received
either spinal or epidural anesthesia. The Mississippi State Department of Health
2

(MSDH), Office of Public Health Statistics (2015) indicate that in 2014 there were a total
of 38,735 live births. If the assumption that 61% of those births were a vaginal delivery
that received either spinal or epidural anesthesia, then approximately 23,628 live births
were performed with the assistance of neuraxial anesthesia in the year 2014. To further
that the MSDH reported each county of Mississippi’s live births, Forrest County had
1,038 births. Assuming that 61% received neuraxial anesthesia for vaginal birth, roughly
633 live births in Forrest County were performed with aid of neuraxial anesthesia. This
number of obstetric patients that may have the potential side effect of nausea/vomiting
and/or pruritus from opioid administration via epidural or spinal anesthesia offers an
assumption of significance to provide the utmost care.
Overview of Literature Review
The obstetric patient that has received a neuraxial analgesic deserves to have
anesthesia care that is based on evidence based practice. The focus of the literature
review is to research the administration of ondansetron intravenously in preventing
nausea/vomiting and reduce the incidence of pruritus. The literature review is key to
establishing the best evidence based practice to implement a change in practice.
PICO, Problem Statement, and Purpose
Will the administration of IV ondansetron to the obstetric patient that has received
opioids via an epidural reduce the incidence of nausea/vomiting and pruritus? The
administration of IV ondansetron within five minutes of successful epidural placement to
the obstetric patient that has received opioids via an epidural will reduce the incidence of
nausea/vomiting and pruritus in the setting of a southeast Mississippi health facility that
has the highest amount of deliveries in the area. This is the PICO statement and will be
3

the focus of the doctoral project. The purpose of this project was to determine the
efficacy of intravenous ondansetron in reducing the incidence of nausea/vomiting and
pruritus post epidural administered opioids in the obstetric patients. Efficacy, in this
project, was defined as the overall effectiveness of ondansetron to relieve or reduce the
incidence of nausea/vomiting and pruritus in this patient population. Comparison will be
made between no administration of ondansetron 5 minutes after epidural placement and
the administration of ondansetron within 5 minutes of epidural placement. One member
of the anesthesia team is using 4mg ondansetron IV within five minutes of epidural
placement, the project will look at the efficacy of ondansetron in reducing epiduralinduced nausea/vomiting and will focus on ondansetron as an alternative medication for
the relief of pruritus. Pruritus is not life-threatening but it can be very frustrating and
burdensome to the patient and may decrease overall patient satisfaction. The effect may
increase in intensity so that it disturbs the patient’s sleep. By determining the efficacy of
ondansetron in preventing nausea/vomiting and an added benefit of reducing the
incidence of pruritus, a practice change can be made to provide future obstetric patients
with the best evidenced based care.
Doctor of Nursing Practice (DNP) Essentials
This project met all eight DNP essentials as described in Appendix A. The two
essentials that were most represented in this project were essentials III and VI. Essential
III, Clinical Scholarship and Analytical Methods for Evidence-Based Practice, was
demonstrated by using analytic methods to critically appraise existing literature on
ondansetron reducing nausea/vomiting and/or pruritus in the obstetric patient, designed
and implemented a process to evaluate the outcomes of current practice, then evaluated
4

quality improvement methodologies, performed research methods to collect appropriate
data, inform, analyze, and the identify gaps, if any, in current practice. Essential VI,
Interprofessional Collaboration for Improving Patient and Population Health Outcomes,
was demonstrated by employing effective communication and collaborative skills with
the information technology (IT) department. Electronic patient information charting
(EPIC) was utilized for data collection and in the development and implementation of
change in the health care system. Collaboration with the IT department was vital in the
inclusion and exclusion of criteria of data that is presented in Chapter III.

5

CHAPTER II – REVIEW OF LITERATURE
A comprehensive review of literature was performed to locate information
regarding the use of the drug ondansetron to reduce incidence of pruritus in obstetric
patients receiving intrathecal opioids. The search consisted of multiple databases
accessed through the University of Southern Mississippi’s (USM) online catalogue. The
databases used were Ovid, Cochrane Library, Pubmed, CINAHL, and Ebscohost. The
search terms and MeSH terms used were ondansetron, Zofran, pruritus, nausea, obstetric,
and epidural. All of these search terms were used interchangeably and in different
combinations for advanced searches that would result in a desired article. Searches were
limited to full text within the past 8 years. Inclusion criteria were that the article must be
written in English and must be relevant to the efficacy of ondansetron in reducing
neuraxial-induced pruritus and nausea. Exclusion criteria were any articles not written in
English, which were not within the past 8 years, and were not relevant to the proposed
topic of study. A total of 136 articles resulted from this and 11 articles were used after
omitting ones based on relevance or criteria.
Cesarean Sections
A prospective, randomized, double-blinded and placebo controlled study by Koju,
Gurung, and Dongol (2015) was conducted over a 5 month period with 50 healthy
parturients who were undergoing caesarean section under spinal anesthesia. The patients
were randomly categorized into placebo group and treatment group. Twenty five
received a placebo, 2ml of normal saline, and the treatment group of 25 received 4mg of
ondansetron. Each group was administered their respective dose 30 minutes prior to
injection of intrathecal morphine. Pruritus and post-operative nausea and vomiting
6

(PONV) scores were observed 24 hours after the administration of intrathecal morphine.
Statistical analysis was done using chi-square test. The placebo group experienced a
significant increased incidence, severity, and need for treatment for pruritus than
compared to the treatment group (88% vs 16% p< 0.001), and in both groups no
participant required any additional medication to treat the pruritus (Koju et al., 2015).
This result demonstrates ondansetrons efficacy on reducing pruritus with neuraxial
morphine. The study was limited to one type of 5HT-3 antagonist with a fixed dose;
however, it efficiently shows that pruritus can be managed by the administration of 4mg
IV ondansetron 30 minutes prior to morphine injected intrathecally. In addition, the risk
of PONV in the placebo group was increased compared to the treatment group (56% vs
8%, p< 0.001) (Koju et al., 2015).
Randomized, double-blind study by Gulhas et al. (2007), was aimed to compare
the effectiveness of lornoxicam and ondansetron for the prevention of intrathecal
fentanyl-induced pruritus in patients undergoing c-section. One hundred and eight
parturients ASA I-II status were given neuraxial analgesia by a combination spinalepidural (CSE) technique. The CSE was performed and all participants received 25mcg
of Fentanyl and 12mg hyperbaric bupivacaine. Three groups were established, group L
received 8mg IV of lornoxicam, group O received 8mg IV of ondansetron, and group P
which received 2ml of normal saline, each group had 36 participants. A Chi-square test
was performed and results from 4 hours until 12 hours postoperatively, the incidence of
pruritus was signiﬁcantly lower for group O when compared to that in group L and group
P (p < 0.05), also the number of patients experiencing no pruritus was significantly
higher in group O than compared to the other groups (Gulhas et al., 2007, p. 161).
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Dong, Soon, Ja-Young, Jae, and Ki (2007), looked at the effectiveness of epidural
administration of ondansetron, rather than intravenously, to reduce pruritus in elective
cesarean deliveries. An animal study was performed on rats first to test for any
neurotoxic side effects of ondansetron administered intrathecally. Upon dissection of the
spinal cord of the rats, there was no specific morphological or histological changes noted.
Eighty patients undergoing cesarean delivery consented and participated in this study.
Forty patients received ondansetron through an epidural (EP) and the remaining forty
received the medication intravenously (IV). The incidence of pruritus was significantly
lower in the EP group (22.5% and 15%) than the IV group (55% and 30%) at 24 and 48
hours post-operatively (p < 0.05) (Dong et al., 2007, pp. 683-687). The administration of
intrathecal administration of ondansetron needs to be evaluated further.
In 2014, Kung et al. performed a prospective, randomized, double-blinded study
to test the efficacy of prophylactic administration of ondansetron in reducing the
incidence of intrathecal morphine-induced pruritus. Ninety participants undergoing
cesarean section were randomized into three groups: placebo group (PLAC), treatment
group (TREAT), or prophylactic group (PROPH). The patients all received the same dose
of spinal anesthetic which included both 25 mcg of fentanyl and 250 mcg of morphine.
Two syringes were prepared as follows: PROPH group: syringe A: ondansetron 8mg
(4ml); syringe B normal saline 4ml; TREAT group: syringe A: normal saline 4ml;
syringe B: ondansetron 8mg (4ml); PLAC group: both syringes were 4ml of normal
saline. Syringe A was administered immediately following the umbilical cord clamping
and syringe B administered in the post-anesthesia care unit (PACU). A visual analog
scale (VAS) was then used to assess nausea, pain, and pruritus in time increments of 30,
8

60, and 120 minutes after arriving to the PACU. The study was terminated before
completion due to lack of statistical evidence from the interim analysis that showed no
effect from ondansetron in relieving pruritus. Statistical analysis was performed by
ANOVA with Bonferroni correction or Fisher’s exact test (Kung et al., 2014, pp. 222236). Limitations to this study were that it was stopped early, intrathecal fentanyl was
used in addition to morphine which deviates from the title suggestion of treatment of
morphine-induced pruritus, and ketorolac, an anti-inflammatory medication, was given
post-operatively and may have helped with the decrease of pruritus.
Other Populations
A systematic review of 15 randomized control trials shows the efficacy of a
prophylactic single intravenous bolus of 5HT-3 receptor antagonists, such as
ondansetron, in reducing pruritus after neuraxial administration of opioids. The 5-HT3
receptor antagonists have been shown to decrease the incidence and the intensity score of
pruritus, primarily when morphine is used as the neuraxial opioid and suggested a
decrease in the treatment of pruritus (Kumar & Singh, 2013). The systematic review did
not suggest that the 5HT-3 receptor antagonists was effective in reducing the incidence of
pruritus after the injection of neuraxial lipid-soluble opioids, such as fentanyl.
A double blind randomized case-control study was done by Jahanbakhsh, Fathi,
and Bazyar (2014) to appraise the effects of ondansetron in preventing pruritus from
intrathecal fentanyl in the orthopedic patient. One hundred and seven participants were
randomly assigned to the case group, which received 8mg of ondansetron IV, and 100
randomly assigned to the control group, which received 4ml of normal saline. After
intrathecal fentanyl administration of 25mcg, the patients were evaluated at 5, 10, 30, 60
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minutes and then hourly up to 6 hours for any side effects. The presence, severity, and
location of pruritus were also evaluated after 2 and 6 hours. The data was analyzed using
Kolmogorov-Smirnov test, student t-test, Mann–Whitney U, chi-square test, Fisher exact
test, and Spearman linear correlation coefficient (Jahanbakhsh et al., 2014). The results
were that the incidence of pruritus was 60% in the control group and 34% in the case
group (Jahanbakhsh et al., 2014). Pruritus among the participants was most prevalent at
the injection site of fentanyl; however, the administration of ondansetron decreased
pruritus at the injection site (Jahanbakhsh et al., 2014). Some of the case group still
experienced severe pruritus. The phenomenon of neuraxial induced pruritus is
undetermined and further studies must be performed to understand its true exact
mechanism of action. It should be noted that these participants were undergoing
orthopedic procedures, not an obstetric procedure, but the results are still promising in
that it establishes a reduction of fentanyl-induced pruritus.
Review of Literature Conclusion
The review of literature has provided evidence that ondansetron is effective in
reducing the incidence and the severity of pruritus associated with intrathecal
administered opioids. There was minimal literature on ondansetron and epidural use, the
literature was older than eight years and was not used. The review of literature states
ondansetron to be a safe and effective alternative to treat intrathecal opioid-induced
pruritus in the cesarean population and also in other patient populations.
Theoretical Framework
The theoretical framework that would best fit this study is the Model for Change
to Evidence Based Practice developed and introduced by Rosswurm and Larrabee (1999).
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The model framework involves six steps which are: 1.) assess need for change in
practice; 2.) link problem with interventions and outcomes; 3.) synthesize best evidence;
4.) design a change in practice; 5.) implement and evaluate the practice change; and 6.)
integrate and maintain the change (Rosswurm & Larrabee, 1999). The overall goal of
this study is to implement a new protocol based on the best evidence-based practice. By
using the framework established by Rosswurm and Larrabee it will allow for a structured
model to provide a change in practice in reducing the incidence of nausea/vomiting and
pruritus with neuraxial administered opioids in the obstetric patient.
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CHAPTER III - METHODOLOGY
For the obstetric patient population, the epidural is an elective anesthetic
procedure that is used to decrease the pain and discomfort. One prominent side effect to
the use of an epidural is pruritus, with an incidence in the obstetric patient of 60-100%
(Kumar & Singh 2013). Ondansetron, an anti-emetic, has been shown to decrease the
incidence of pruritus in the review of literature. The next sections will present the
proposed method design, data collection, and statistical analysis that will be used so that
the necessary information to determine if this alternative treatment would be beneficial in
decreasing the incidence of pruritus in the obstetric patients receiving epidural
administered opioids.
Population
Inclusion criteria was the obstetric patient receiving an epidural opioid, are
between the ages 20 and 40, English speaking, and vaginal delivery with an epidural.
Exclusion included all of the obstetric patients that did not receive an epidural
administered opioid and any patients that had a cesarean section. Exclusion criteria also
included obstetric patients that are younger than 20 years of age and older than 40 years
of age, non-English speaking patients.
Setting
A 512-bed Level II trauma hospital in southeast Mississippi will be the facility in
which the data is collected. Retrospective chart analysis was used and the process of
collecting the data was important in determining the efficacy of the study.
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Design
The study used a retrospective chart review coupled with quantitative statistical
analysis to determine if the administration of IV ondansetron preemptively reduced the
incidence of nausea and also reduce the incidence of pruritus following an epidural
administered opioid. Upon completion of the data collection process, an online sample
size calculator was used to determine the sample size based on the number of the total
population, the confidence level, and the confidence interval.
A benefit of this study is that by using a retrospective chart analysis there were no
patient interactions and no intervention performed. Patient safety was advocated,
meaning the patients used in the study will be at no risk for harm. Observations were
made for obstetric patients who had pruritus and/or nausea after an epidural.
Data Collection
Successful Institutional Review Board (IRB) approval from the selected health
care facility and then IRB approval from the University of Southern Mississippi, access
to patient’s electronic medical record was granted. All data recovered from the medical
record was de identified ensuring confidentiality. The time period requested was
composed of two parts. The first part was to research from February 1, 2015 to August
31, 2015, this was to collect and observe data when the obstetric physicians were in
charge of epidural management. The second part was from February 1, 2016 to August
31, 2016, this was to collect and observe the anesthesia epidural management. Data
collection recorded which medication treatment was given, either ondansetron or any
other medication used and then record the outcome of the treatment and determine the
effectiveness, if any, of the medications
13

All data collection was stored and de-identified on a password protected personal
computer, and data was disposed of by shredding any paper documents or deleted from
computer six months after all graduation requirements have been met.
Statistical Analysis
A t-test can be applied to establish two groups are statistically different from each
other. The two groups can be classified as no administration of ondansetron and
administration of ondansetron and observing the incidence of pruritus and/or nausea of
the two groups. Power analysis calculator provided on https://www.aitherapy.com/psychology-statistics/sample-size-calculator was used to estimate the
appropriate sample size (AI-Therapy Statistics, 2016). A one-tailed t-test, with
independent groups, effect size of 0.6, significance level (α) of 0.05, and power of 0.8
determined that a sample size of 72 (36 in each group) is sufficient to produce statistical
evidence that the two groups are statistically different. Additionally an odds ratio was
utilized to determine the odds that a particular outcome will occur. Administration of
ondansetron can be a variable and the odds ratio can predict the odds that the outcome of
decreased nausea/vomiting and pruritus can occur. This can be further compared to no
administration of ondansetron and determining the odds that the outcome decreased
nausea/vomiting and pruritus can occur. Based upon the significance level, the validity
of the quantitative study was established and included in the project.
Conclusion
In conclusion, a retrospective chart analysis was used to determine the efficacy of
ondansetron relieving pruritus and/or nausea compared to that of diphenhydramine in the
obstetric patient that has received epidural administered opioids. This methodology does
14

not place the patient’s safety and health at risk. Inclusion criteria for the project was
stated and there will be no breech in patient confidentiality. Statistical analysis ultimately
determined if the outcomes of collected data has validity and significant statistical
evidence that ondansetron is more effective in preemptively reducing the incidence of
nausea and vomiting and in addition reduce the incidence of epidural opioid-induced
pruritus in the obstetric patient.
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CHAPTER IV – ANALYSIS OF DATA
Results
A retrospective chart analysis was performed to identify the efficacy of
ondansetron in reducing the incidence of pruritus post epidural administered opioids in
the obstetric patient. The software Electronic Patient Identification Chart (EPIC) was
used to view the patient charts that met the inclusion criteria. The facility was unable to
offer the patient charts requested for February, 2015 to August, 2015. The only available
charts granted permission to review were from the dates of February 2, 2016 until August
31, 2016. A total of 605 (N=605) charts met the criteria and after further evaluation only
a total of 24 (n=24) patients were administered ondansetron within the five minute time
parameter as established in the data collection tool (Appendix D). Additionally 581
(n=581) patients were not administered ondansetron and used in the statistical analysis.
Demographics
Table 1
Demographics of Patients that Received Ondansetron
Characteristics

Number

Percentage

24

100

24

100

Delivery Method
Vaginal
Anesthetic
Epidural
Age
Mean

28.3

Range

21-39
16

All patient information was collected using EPIC and was de-identified on a
personal password protected computer. No identifiable patient information was removed
from the facility. The patient demographics are listed in Table 1, and illustrate that the
patients were within the parameters of the inclusion criteria.
Relevant Results
Of the 24 patients that received ondansetron five minutes after epidural placement
only one patient experienced pruritus and required administration of 25mg
diphenhydramine IV. The patient received the medication 7 hours post epidural
placement. The incidence of pruritus in those patients that received ondansetron was
4.17%. In addition, four patients also needed additional treatment for nausea/vomiting.
One patient received 12.5mg Phenergan IV and three patients received another dose of
4mg ondansetron IV. The average time onset of nausea/vomiting in these four patients
was 9 hours post epidural placement. The incidence of nausea/vomiting in this group was
16.67%.
It was observed that in the group of 581 patients involved in this study that did not
receive ondansetron within 5 minutes of epidural placement only 6 patients required
treatment of pruritus with diphenhydramine, 5 patients received 25mg orally and one
patient received 25mg IV, and one patient experienced severe pruritus and required a
total of four doses of 25mg diphenhydramine orally. The other five in the group only
required one dose. The group that did not receive ondansetron within 5 minutes of
epidural placement had an incidence of pruritus of 1.03%. The average time onset of
pruritus was 8.34 hours after epidural placement. It was noted that in this group 105
patients experienced nausea/vomiting. This is an incidence of 18.07%. The average time
17

onset of nausea/vomiting in these patients was 4.49 hours. By doing simple probability,
based on this sample group, it was determined that the odds of having pruritus are 4.18
times greater for obstetric patients who did receive ondansetron. This was attributed to
the fact that the ondansetron group had a pruritus incidence of 4.17% and compare that to
the no administration of ondansetron group which had an incidence of 1.03%. It was also
determined that the odds of having nausea/vomiting are 1.1 times greater for obstetric
patients who did not receive ondansetron. Based on this sample size of the population
there is an increased odds of having pruritus with pre-treatment of ondansetron. There
was however a very small increased odds of having nausea/vomiting with no pretreatment of ondansetron.
Data Analysis
The initial statistical analysis test was originally a one-sided t test. This was
further evaluated and was determined that this test would be insufficient and a forward
logistic regression along with an odds ratio test would be the optimal test to perform.
Forward logistic regression was conducted to determine if the independent variable
(ondansetron) is a predictor of pruritus and nausea/vomiting in obstetric patients that
received opioids via an epidural.
Pruritus
Regression results indicated that the overall model fit of the predictor
(ondansetron) was reasonably good (-2 Log likelihood = 75.128) and was not statistically
reliable in distinguishing between variables [Independent variable (ondansetron) and
dependent variable (pruritus)] [x²(1) = 1.222, p = .269]. The model is accurate in
classifying 98.8% of the participants. Regression coefficients are presented in Table 2.
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Wald statistics indicated that ondansetron did not significantly predict pruritus. Odds
ratio for the variable indicated very little change in the likelihood of patient experiencing
pruritus.
Table 2
Regression Coefficients for Pruritus

Ondansetron
Constant

B
-1.427
-3.135

Wald
1.681
9.422

df
1
1

p
.195
.002

Odds Ratio
.228

Nausea/Vomiting
Regression results indicated that the overall model fit of the predictor
(ondansetron) was debatable (-2 Log likelihood =573.669) and was not statistically
reliable in distinguishing between variables [Independent variable (ondansetron) and
dependent variable (nausea/vomiting)] [x²(1) = .039, p = .844]. The model correctly
classified 81.8% of the cases. Regression coefficients are presented in Table 3. Wald
statistics indicated that ondansetron did not significantly predict nausea/vomiting. Odds
ratio for the variable indicated very little change in the likelihood of patient experiencing
nausea/vomiting.
Table 3
Regression Coefficients for Nausea/Vomiting

Ondansetron
Constant

B
.110
-1.609

Wald
.039
8.634

df
1
1
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p
.844
.003

Odds Ratio
.894

Data Evaluation
The overall purpose of this project was to determine if administration of
ondansetron within five minutes of successful placement of an epidural would decrease
incidence of nausea/vomiting and pruritus in the obstetric patient. After evaluating the
statistical analysis for this sample it was determined that the administration of
ondansetron does not reduce the incidence of nausea/vomiting and pruritus in the
obstetric patient post epidural administered opioids.
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CHAPTER V – DISCUSSION
Summary of Major Findings
As stated in Chapter IV, after statistical analysis the administration of ondansetron
within five minutes after epidural placement did not demonstrate significant statistical
evidence that it decreases the incidence of nausea/vomiting and pruritus in the obstetric
patient (Pruritus p= .195 and Nausea/Vomiting p= .844).
Limitations and Barriers
Limitations
Limitations and barriers to this project were that it was an overall small sample
size of patients that did receive ondansetron five minutes post epidural (n= 24). The
facility that was used in this project utilized an epidural infusion of Naropin 0.25% plus
0.125mcg/ml of fentanyl at a rate of 10-18 ml/hour. The current practice used in this
facility does not use opioids in the loading dose of the epidural. The only exposure of
opioids the obstetric patient receives comes from the epidural infusion which is a
minimal dose and a slow rate of infusion. This is a limitation to this project because the
patient is only exposed to a minimal concentration of opioids. A history of postoperative nausea/vomiting (PONV) in the obstetric patients was not observed and could
have factored in the outcome. Also, once the epidural was discontinued no more
observations of nausea/vomiting and pruritus was recorded in the data collection. There
may have been more instances of nausea/vomiting and pruritus after the epidural was
discontinued and could have had an impact on the statistical result.

21

Barriers
A barrier to this project was that only one CRNA administered ondansetron
within minutes post epidural, and in some instances the administration was after five
minutes and did not meet the inclusion criteria and was excluded from the sample size. A
technology barrier was present in that there was no electronic charting present for the
requested dates of February 1, 2015 to August 31, 2015. The facility used paper charting
during those dates and were not able to provide these charts for the statistical analysis and
could add more statistical validity to the project.
Implications of Clinical Scholarly Project
Based on the statistical analysis, the implications on nursing practice is that it
provided anesthesia providers some evidence that ondansetron is not effective in
decreasing the incidence of nausea/vomiting and pruritus post epidural administered
opioids in the obstetric patient. The results of this project will provide the obstetric
patients with a more satisfying overall stay in the hospital which will enhance quality
improvement. For future studies, a needs assessment may need to done first to determine
what the actual incidence of nausea/vomiting and pruritus is in post epidural administered
opioids in the obstetric patient. If there is a significant incidence (~ 50% or greater) of
nausea/vomiting or pruritus the clinical question will ondansetron reduce the incidence
on nausea/vomiting and pruritus can be utilized and further studied. Further studies need
to include a larger sample size to add more strength in the statistical analysis. A
recommendation of a longer time frame than five minutes to administer ondansetron post
epidural can be further studied for any statistical difference. Suggested future studies
may want to observe if parity is a variable that can increase or decrease incidence of
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nausea/vomiting and pruritus. A history of PONV could be included in further studies to
determine its impact on incidence of nausea/vomiting post epidural. Finally, a study to
determine if there is an increase in the incidence of nausea/vomiting and pruritus in either
duramorph or fentanyl administered via epidural in the obstetric patient. In the future, the
author can perform either a pilot study or randomized control trial to add more statistical
validity to this project.
Dissemination of the findings was provided to the key stakeholders of the
anesthesia department at the healthcare facility where the data was collected. Statistical
analysis, interpretation of results, and future recommendations was presented.
Dissemination of results and recommendations for future studies was also presented to
students in the nurse anesthesia program at The University of Southern Mississippi. In
the future, the author can present findings to a state chapter or national anesthesia
association.
Conclusions
The goal of this project was to determine the efficacy of intravenous ondansetron
in reducing the incidence of nausea/vomiting and pruritus post epidural administered
opioids in the obstetric patients. A retrospective chart review was performed and
statistical analysis revealed in this sample that ondansetron is not statistically significant
in reducing either nausea/vomiting or pruritus. This project can provide key stakeholders
current evidence-based knowledge regarding nausea/vomiting and pruritus post epidural
in the obstetric patient.
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APPENDIX A – DNP Essentials
Essential I: Scientific Underpinnings for Practice

Essential II: Organizational and Systems
Leadership for Quality Improvement and Systems
Thinking
Essential III: Clinical Scholarship and Analytical
Methods for Evidence-Based Practice

Essential IV: Information Systems/Technology
and Patient Care Technology for the Improvement
and Transformation of Health Care
Essential V: Health Care Policy for Advocacy in
Health Care

Essential VI: Interprofessional Collaboration for
Improving Patient and Population Health
OutcomesEssential VII: Clinical Prevention and Population
Health for Improving the Nation’s Health
Essential VIII: Advanced Nursing Practice

This capstone project described actions and
advanced strategies to help alleviate the
phenomena of post epidural administered opioid
induced nausea/vomiting and pruritus.
This capstone project developed and evaluated
care delivery that meet current and future needs of
the obstetric patient who receives epidural
administered opioids.
This capstone project used analytic methods to
critically appraise existing literature on
ondansetron reducing nausea/vomiting and/or
pruritus in the obstetric patient, designed and
implemented a process to evaluate the outcomes of
current practice, then evaluated quality
improvement methodologies, performed research
methods to collect appropriate data, inform,
analyze, and the identify gaps in current practice.
This capstone project demonstrated the conceptual
ability to develop and execute an evaluation plan.
This capstone project developed, evaluated, and
provided leadership for health care policy and
helped shape health care delivery to the obstetric
patient who has received epidural administered
opioids.
This capstone project employed effective
communication and collaborative skills in the
development and implementation of change in the
health care system.
Dissemination of findings to state chapter or
national anesthesia association upon completion of
project
This capstone designed, implemented, and
evaluated therapeutic interventions based on
nursing science, to reduce the incidence of post
epidural opioid-induced nausea/vomiting and
pruritus in the obstetric patient population.
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APPENDIX B – USM IRB Approval Letter
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APPENDIX C – Facility IRB Approval Letter
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APPENDIX D – Data Collection Tool

Age

Epidural
assisted
vaginal
delivery

Ondansetron
Ondansetron not
administered within administered
5 minutes of
epidural

Subject1
Subject2
Subject3
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Any other
medications used
to treat N/V or
pruritus

APPENDIX E – Literature Matrix

AUTHOR

YEAR

DESIGN

FRAMEWORK

SAMPLE

FINDINGS

Dong, W. H., Soon,
W. H., Ja-Young,
K., Jae, W. L., &
Ki, K. J.

2007

Not specified

N/A (No
Theoretical
Framework used)

N= 80 ASA I
elective cesarean
section n=40 EP
ondansetron n=40
IV ondansetron

The incidence of
pruritus was
significantly lower in
the EP group (22.5%
and 15%) than the IV
group (55% and 30%) at
24 and 48 hours postoperatively (p < 0.05)

Jahanbaksh, S. S.,
Fathi, M., &
Bazyar, S.

2014

double blind
randomized casecontrol study The
data was
analyzed using
KolmogorovSmirnov test,
student t-test,
Mann–Whitney
U, chi-square
test, Fisher exact
test, and
Spearman linear
correlation
coefficient.

N/A (No
Theoretical
Framework used)

N= 207 ASA I, II,
III receiving lower
extremity
orthopedic surgery
n= 107 ondansetron
IV (case group) n=
100 normal saline
IV (control group)
all receiving 25mcg
of fentanyl
intrathecally

The results were that the
incidence of fentanylinduced pruritus was
60% in the control
group and 34% in the
case group

Gulhas, N., Erdil,
F. A., Sagir, O.,
Gedik, E., Togal,
T., Begec, Z., &
Ersoy, M. O.

2007

randomized
double blind
study , chi-square
test

N/A (No
Theoretical
Framework used)

N=108, ASA I, II,
cesarean section,
CSE 25mcg
Fentanyl, n=36
group L (8mg
lornoxicam), n=36
group O (8mg
ondansetron), n=36
group P (2ml
normal saline)

the incidence of pruritus
was signiﬁcantly lower
for group O when
compared to that in
group L and group P (P
< 0.05), also the number
of patients experiencing
no pruritus was
significantly higher in
group O than compared
to the other groups
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Koju, R. B.,
Gurung, B. S., &
Dongol, Y

2015

prospective,
randomized,
double-blinded
and placebo
controlled study
chi-square test

N/A (No
Theoretical
Framework used)

N=50 ASA I, II
caesarean section
n=25 placebo (2ml
normal saline)
n=25 treatment
(4mg ondansetron)
receiving 0.2mg of
morphine
intrathecally

The placebo group
experienced a
significant increased
incidence, severity, and
need for treatment for
morphine-induced
pruritus than compared
to the treatment group
(88% vs 16% P <
0.001), and in both
groups no participant
required any additional
medication to treat the
pruritus

Kumar, K., &
Singh, S. I.

2013

systematic review
of 15 randomized
control trials

N/A (No
Theoretical
Framework used)

Not specified

The 5-HT3 receptor
antagonists have been
shown to decrease the
incidence and the
intensity score of
pruritus, primarily when
morphine is used as the
neuraxial opioid and
suggested a decrease in
the treatment of pruritus.
did not suggest that the
5HT-3 receptor
antagonists was
effective in reducing the
incidence of pruritus
after the injection of
neuraxial lipid-soluble
opioids, such as
fentanyl.
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Kung, A. T., Yang,
X., Li, Y.,
Vasudevan, A.,
Pratt, S., & Hess, P.

2014

prospective,
randomized,
double-blinded
study Statistical
analysis was
performed by
ANOVA with
Bonferroni
correction or
Fisher’s exact
test.

N/A (No
Theoretical
Framework used)
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N=90 ASA I, II n
(PLAC)= 26, n
(TREAT)= 32, n
(PROPH)= 24
undergoing
cesarean section
were randomized
into three groups:
placebo group
(PLAC), treatment
group (TREAT), or
prophylactic group
(PROPH). The
patients all
received the same
dose of spinal
anesthetic which
included both 25
mcg of fentanyl
and 250 mcg of
morphine.

The study was
terminated before
completion when the
interim analysis showed
no effect. . Limitations
to this study were that it
was stopped early,
intrathecal fentanyl was
used in addition to
morphine which
deviates from the title
suggestion of treatment
of morphine-induced
pruritus, and ketorolac,
an anti-inflammatory
medication, was given
post-operatively and
may have helped with
the decrease of pruritus
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